

September 30, 2014



Arch Therapeutics Will Present at the Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014

WELLESLEY, MA -- (Marketwired) -- 09/30/14 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of the AC5 Surgical Hemostat™, announced that it will be featured as a presenting company at the 7th Annual Livingston Securities Life Sciences Stakeholders Summit on October 1, 2014 at the Cira Center in Philadelphia, PA.

Chief Executive Officer, Terrence W. Norchi, MD, will provide a corporate overview and update. Dr. Norchi will also discuss the importance of developing a hemostatic agent that is effective in patients prescribed anti-coagulant or anti-platelet therapy, which are commonly known as blood thinners and are taken by millions of Americans. AC5™ has recently been shown to be effective in stopping bleeding in animals on an anticoagulant in two separate studies, including one performed by an independent third-party research group. In these studies, the measured time to hemostasis (TTH) in animals administered therapeutic doses of heparin was rapid and comparable to the TTH in those animals not administered the anticoagulant. TTH is a measure of the time required for bleeding to stop after administration of the product.

The current presentation will be available on the corporate website (www.archtherapeutics.com).

About Arch Therapeutics, Inc.

Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship development stage product candidate, known as the AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.

About Livingston Securities

Livingston Securities (www.livingstonsecurities.com) was founded in 2009 as a boutique investment bank & broker/dealer focused on three goals:

- Financing the nanotechnology revolution
- Changing the way that innovation is financed on Wall Street
- Connecting you with your local innovation economy

Livingston Securities is dedicated to providing corporate finance and strategic advisory services to corporate clients and sales, trading and related services to institutional investors and high net worth individuals who focus on disruptive technologies and their impact on

healthcare, energy, infrastructure and other leading sectors of the American and global economy.

Livingston Securities' goal is to provide a unique perspective and expertise on investments in nanotechnology and in companies that are commercializing and/or impacted by scientific advances in the emerging field of nanotechnology.

Notice Regarding Forward-Looking Statements

This news release contains "forward-looking statements" as that term is defined in Section 27(a) of the Securities Act of 1933, as amended, and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release that are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, references to novel technologies and methods, our business and product development plans and projections, or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with developing new products or technologies and operating as a development stage company, our ability to retain important members of our management team and attract other qualified personnel, our ability to raise the additional funding we will need to continue to pursue our business and product development plans, our ability to develop and commercialize products based on our technology platform, and market conditions. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in the reports and other documents we file with the SEC, available at www.sec.gov.

On Behalf of the Board,
Terrence W. Norchi, MD
Arch Therapeutics, Inc.

Contact:

ARTH Investor Relations
Toll Free: +1-855-340-ARTH (2784) (US and Canada)
Email: investors@archtherapeutics.com
Website: www.archtherapeutics.com

or

Richard Davis
Chief Financial Officer
Arch Therapeutics, Inc.
Phone: 617-431-2308
Email: rdavis@archtherapeutics.com

Website: www.archtherapeutics.com

Source: Arch Therapeutics, Inc.